Alarmins are endogenous intracellular molecules released from damaged, stressed, or necrotic cells that function as danger signals to activate the innate immune system. They represent a functionally defined subclass of DAMPs (Damage-Associated Molecular Patterns) distinguished by their ability to bind specific receptors and trigger cytokine-like signaling cascades. Unlike passive damage signals, alarmins actively orchestrate both inflammatory and resolution responses depending on their post-translational modifications and tissue context.
Think of alarmins as the emergency broadcast system inside a burning building. Normally, these announcements stay inside the control room (the cell). But when fire breaks out (necrosis, severe stress), the loudspeakers get blown out into the street, broadcasting emergency signals to everyone in the neighborhood. Fire trucks (neutrophils), ambulances (macrophages), and police (dendritic cells) all respond because the broadcast uses specific radio frequencies (receptors like TLR4, RAGE, IL-33R) that emergency services are tuned to listen for.
Here's the critical detail: the message changes depending on how damaged the loudspeaker is. A pristine loudspeaker (reduced, non-oxidized HMGB1) broadcasts "send repair crews" (pro-regenerative signals). A smoke-damaged one (oxidized HMGB1) screams "full alarm, send everything" (pro-inflammatory). A partially melted one (acetylated IL-33) might broadcast conflicting messages. The same alarmin can be a call for help or a fire alarm depending on its chemical modifications—and the immune system reads these modifications like different emergency codes.
Alarmins operate through four distinct pathways depending on the alarmin type and its post-translational state:
1. HMGB1 Pathway (Prototypical Alarmin):
- Nucleus → passive release during necrosis OR active secretion via non-classical pathway (no ER/Golgi)
- Reduced HMGB1 → binds CXCL12 → CXCR4 on stem cells → tissue regeneration
- Oxidized HMGB1 → TLR4/RAGE on macrophages → MyD88 → NF-κB → IL-6, TNF-α, IL-1β
- Acetylated HMGB1 (active secretion) → RAGE → sustained inflammation
2. IL-33 Pathway (Epithelial/Endothelial Alarmin):
- Nuclear constitutive expression → released during necrosis (full-length IL-33)
- Neutrophil proteases cleave IL-33 → 10-fold increase in activity
- IL-33 → ST2 receptor (IL-33R) on Th2, mast cells, innate lymphoid cells (ILC2)
- ST2 signaling → MyD88 → NF-κB + AP-1 → IL-5, IL-13, IL-4 (Type 2 immunity)
- sST2 (soluble decoy receptor) → negatively regulates IL-33 activity
3. IL-1α Pathway (Dual-Function Alarmin):
- Constitutively expressed in epithelial cells
- Cell death → release of pro-IL-1α (no cleavage required for activity, unlike IL-1β)
- IL-1α → IL-1 receptor → MyD88 → NF-κB → inflammatory gene transcription
- Nuclear IL-1α → chromatin binding → transcriptional regulation (non-alarmin function)
4. Heat Shock Protein Pathway:
- Normally intracellular chaperones (Heat shock proteins 60, 70, 90)
- Cellular stress → active secretion via exosomes OR passive necrotic release
- Extracellular HSP60/70 → TLR4, TLR2 → MyD88/TRIF → NF-κB/IRF3 → inflammatory cytokines
- HSP-peptide complexes → cross-presentation by dendritic cells → CD8+ T cell activation
graph TD
A[Cell Damage/Necrosis] --> B[Alarmin Release]
B --> C[HMGB1]
B --> D[IL-33]
B --> E["IL-1α"]
B --> F[HSPs]
C --> C1{Redox State?}
C1 -->|Reduced| C2[CXCR4 Signaling]
C1 -->|Oxidized| C3[TLR4/RAGE]
C2 --> C4[Regeneration & Repair]
C3 --> C5["NF-κB Activation"]
D --> D1[ST2 Receptor]
D1 --> D2[MyD88]
D2 --> D3[Type 2 Cytokines]
D3 --> D4[IL-5, IL-13, IL-4]
E --> E1[IL-1R]
E1 --> E2[MyD88]
E2 --> C5
F --> F1[TLR2/TLR4]
F1 --> F2[MyD88/TRIF]
F2 --> C5
C5 --> G[Pro-inflammatory Cytokines]
G --> H[Leukocyte Recruitment]
G --> I[Vascular Permeability]
G --> J[Acute Phase Response]
D4 --> K[Eosinophil Recruitment]
K --> L[Tissue Remodeling/Allergy]
Post-Translational Modifications Alter Function:
- Acetylation (lysine residues) → enhances secretion, maintains pro-inflammatory state
- Oxidation (cysteine residues on HMGB1) → determines CXCR4 vs TLR4 binding
- Phosphorylation → nuclear-cytoplasmic shuttling
- Proteolytic cleavage → activation (IL-33) or inactivation (HMGB1 by thrombin)
Context-Dependent Signaling:
Alarmins represent the molecular bridge between sterile tissue damage and chronic inflammatory diseases—a core concept in understanding chronic low-grade inflammation and evolutionary mismatch. In clinical practice, alarmin biology explains three critical phenomena:
1. Sterile Inflammation Cascade (Metamodel 1 - Inflammation):
Conditions like osteoarthritis, atherosclerosis, NASH, and chronic pain involve persistent alarmin release from damaged tissue in the absence of infection. HMGB1 levels correlate with disease severity in rheumatoid arthritis (>10 ng/mL serum indicates active disease). This explains why anti-inflammatory interventions must address damage repair, not just immune suppression—stopping the alarmin broadcast requires fixing the building, not just silencing the alarm.
2. Wound Healing Dysregulation:
The redox state of HMGB1 determines whether tissue regenerates or scars. Reduced HMGB1 promotes stem cell recruitment and angiogenesis; oxidized HMGB1 drives fibrosis via persistent TLR4 activation. Interventions that modulate oxidative status (glutathione support, polyphenols, controlled hypoxia) can theoretically shift alarmin function toward resolution. This is clinically relevant in fibrosis, keloid formation, and non-healing diabetic wounds.
3. Autoimmune Disease Initiation:
Antigen spreading in autoimmune disease often begins with alarmin-driven activation of dendritic cells presenting self-antigens from damaged tissue. IL-33 drives Type 2 immunity and is elevated in asthma (>300 pg/mL BAL fluid), atopic dermatitis, and eosinophilic esophagitis. HMGB1 is implicated in systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease. The selfish immune system interprets chronic alarmin signals as persistent threat, maintaining autoimmune activation.
4. Therapeutic Targets:
- Anti-HMGB1 strategies: Glycyrrhizin (licorice extract) binds HMGB1, preventing receptor engagement; ethyl pyruvate reduces HMGB1 release
- IL-33 blockade: Anti-ST2 antibodies in development for asthma, COPD
- Redox modulation: N-acetylcysteine, alpha-lipoic acid, dietary polyphenols shift HMGB1 toward reduced (pro-regenerative) state
- HSP inhibition: Quercetin modulates HSP expression
Evolutionary Context:
Alarmins evolved to detect cellular damage from trauma, infection, or toxin exposure—threats present throughout human evolution. Modern mismatch diseases (metabolic syndrome, chronic stress, sedentary behavior, processed food exposure) generate constant low-level alarmin release without the acute damage-repair cycle these molecules evolved to manage. The result is chronic low-grade inflammation that drives metaflammation, neuroinflammation, and accelerated aging.
Diagnostic Utility:
- Serum HMGB1 >10 ng/mL: active inflammatory disease
- Calprotectin (S100A8/A9, alarmin family): >250 μg/g feces indicates inflammatory bowel disease
- Plasma IL-33: >500 pg/mL associated with severe asthma exacerbation
- Monitoring alarmin levels can track treatment response and disease activity
- Alarmins are a subset of DAMPs distinguished by defined receptor-mediated cytokine-like functions, not just generic "damage signals"
- Major alarmins include HMGB1, IL-33, IL-1α, S100 proteins (calprotectin, S100A12), Heat shock proteins (HSP60, HSP70, HSP90), defensins, and uric acid crystals
- HMGB1 exists in three redox states: fully reduced (all-thiol, pro-regenerative), disulfide (cytokine-inducing), and sulfonyl (immunologically inert)
- IL-33 is stored constitutively in endothelial and epithelial cell nuclei; it is activated by proteolytic cleavage during necrosis (no inflammasome required, unlike IL-1β)
- Post-translational modifications (acetylation, oxidation, phosphorylation, citrullination) regulate alarmin secretion, receptor binding, and biological activity
- Alarmins activate multiple receptor systems: TLR2, TLR4, RAGE, ST2, IL-1 receptor, CD24, TREM-1
- Chronic alarmin release without resolution → trained immunity reprogramming of monocytes/macrophages via epigenetic changes at H3K4me3 and H3K27ac marks
- S100A8/A9 (calprotectin) functions as both alarmin and antimicrobial through zinc/calcium chelation (nutritional immunity)
- Extracellular ATP acts as an alarmin via P2X7 receptor → NLRP3 inflammasome activation
- Alarmins are therapeutic targets: anti-HMGB1 (glycyrrhizin), anti-IL-33 (anti-ST2), HSP modulators (quercetin)
- Serum HMGB1 correlates with mortality in sepsis (>50 ng/mL associated with poor outcome)
- Alarmin signaling explains "danger theory" of immunity (Polly Matzinger): immune system responds to danger, not just "non-self"
- HMGB1 — Prototypical alarmin with redox-dependent dual function: regenerative when reduced, inflammatory when oxidized
- DAMPs — Alarmins are the receptor-defined, cytokine-functional subclass of damage-associated molecular patterns
- PAMPs — Alarmins and pathogen patterns synergize through shared receptors (TLR4, RAGE) to amplify innate immunity
- RAGE — Multi-ligand receptor for HMGB1, S100 proteins, AGEs; key alarmin signaling node in chronic inflammation
- Low-grade inflammation — Chronic alarmin release from metabolic stress, oxidative damage, and cellular senescence drives persistent LGI
- TLR4 — Primary receptor for oxidized HMGB1 and HSP60/70; links sterile inflammation to innate immune activation
- NF-κB — Central transcription factor activated by most alarmin pathways; regulates inflammatory cytokine gene expression
- IL-6 — Downstream cytokine product of alarmin-TLR4-NF-κB signaling; amplifies acute phase response
- IL-1β — Distinguished from IL-1α (alarmin) by requirement for inflammasome cleavage; both signal through same receptor
- Inflammasome — NLRP3 inflammasome activated by alarmin signals (extracellular ATP, uric acid crystals) to process IL-1β
- Chronic low-grade inflammation — Alarmins provide molecular mechanism for sterile LGI in obesity, atherosclerosis, neurodegeneration
- Neuroinflammation — HMGB1 crosses damaged blood-brain barrier, activating microglia via TLR4/RAGE
- Fibrosis — Oxidized HMGB1 drives persistent myofibroblast activation and collagen deposition in chronic wounds
- Wound healing — Reduced HMGB1 promotes tissue regeneration via CXCR4 signaling and stem cell recruitment
- Trained immunity — Chronic alarmin exposure epigenetically reprograms monocytes, altering subsequent inflammatory responses
- Senescence — Senescent cells secrete alarmins as part of SASP (senescence-associated secretory phenotype)
- Oxidative stress — Determines HMGB1 redox state; shifts alarmin function from regenerative to inflammatory
- Heat shock proteins — Dual-function molecules: intracellular chaperones and extracellular alarmins activating TLR2/4
- Autoimmune disease — Alarmins activate dendritic cells presenting self-antigens, driving autoimmune priming (SLE, RA)
- Mast cells — ST2+ mast cells respond to IL-33 alarmin with Type 2 cytokine release (allergy, asthma)
- Dendritic cells — Professional APCs activated by alarmins to present damage-associated antigens and prime T cells
- Neutrophils — Respond to alarmin gradients; proteolytically activate IL-33 during tissue damage
- Macrophages — M1 polarization driven by oxidized HMGB1-TLR4 signaling; alarmin clearance via phagocytosis
- Specialized pro-resolving mediators — SPMs antagonize alarmin signaling, promoting efferocytosis and resolution
- Efferocytosis — Clearance of apoptotic cells prevents secondary necrosis and alarmin release
- Necroptosis — Programmed necrosis pathway releases alarmins (vs apoptosis which contains intracellular contents)
- Calprotectin — S100A8/A9 alarmin used as fecal biomarker for intestinal inflammation in IBD
- Uric acid — Crystalline DAMP/alarmin activating NLRP3 inflammasome in gout
- AGEs — Advanced glycation end-products signal through RAGE alongside HMGB1 in diabetic complications
- Metabolic syndrome — Adipocyte necrosis releases alarmins, driving adipose tissue inflammation and insulin resistance
- Atherosclerosis — Cholesterol crystals and necrotic core release alarmins, perpetuating plaque inflammation
- Rheumatoid arthritis — Synovial HMGB1 and S100A8/A9 drive joint inflammation; therapeutic targets
- COVID-19 — Severe cases show elevated HMGB1 and IL-33; alarmin storm contributes to ARDS
- Sepsis — HMGB1 peaks 24-48h after infection; late mediator of septic shock and organ failure
- Cytokine storm — Alarmins amplify cytokine responses in severe infections and immune dysregulation
- Post-translational modification — Acetylation, oxidation, phosphorylation regulate alarmin localization, secretion, and receptor binding
- Gut permeability — Intestinal barrier damage releases IL-33 and HMGB1, linking leaky gut to systemic inflammation
- Module 1 — Introduction to danger signals, DAMPs, and AMPs framework (Metamodel 0)
- Module 3 — Role in chronic inflammation and diagnostic application